UPM Annual Report 2024, Corporate Governance Statement and Remuneration Report published Essity Included in S&P Global Sustainability Yearbook 2025 and Dow Jones Sustainability Index AF&PA Responds to 25% Tariffs on Canada and Mexico Sonoco Showcases its Award-Winning Paper Can ...
https://annual-report.bms.com/assets/bms-ar/documents/2023/2023-bms-financial-report.pdf https://www.astrazeneca.com/content/dam/az/PDF/2022/fy/Full-year-and-Q4-2022-results-announcement.pdf https://www.astrazeneca.com/content/dam/az/PDF/2023/fy/Full-year-and-Q4-2023-results-announcement...
Annual profits - Rate of surprise My WatchlistMost popular (10)My previous session (0) NVIDIA CORPORATION +2.63% UNICREDIT S.P.A. +1.57% COMMERZBANK AG +1.35% APPLE INC. +1.27% AMD (ADVANCED MICRO DEVICES) +1.15% META PLATFORMS, INC. ...
Chart represents JBTM Revenue and Revenue Estimate over Annual period The chart has 1 X axis displaying time periods. The chart has 1 Y axis displaying values. Data ranges from 0 to 3685400000.. 0800M1.6B2.4B3.2B4B Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024 (E)Dec 2025 (E)...
John Bean Technologies Corporation (JBT) Q3 2023 Earnings Call TranscriptSA TranscriptsWed, Oct. 25, 2023 See All Transcripts » Investor Presentations Sorry, this data cannot be displayed at the moment. JBTM SEC Filings Type:All JBT Marel Corporation (JBTM) - SC 13G/A - Amended Statement...
Verastem Oncology Announces Multiple Data Presentations At Society Of Gynecologic Oncology 2025 Annual Meeting On Women's CancerFeb. 20RE B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy RatingJan. 31MT Verastem Names Matthew E. Ros as COOJan. 15MT ...
Annual Dividend Yield — totalindividual payouts 2023 ‡‡‡ 2022 ‡‡‡ 2021 ‡‡‡ 2020 ‡‡‡ 2019 ‡‡‡ 2017 ‡‡‡ predictions in italic, special payouts not included in total or ratios Assets vs Liabilities 202120222023Q'24 Cash 100.26 87.89 137.13 ...
-3.78%+33.08% Feb. 20Verastem Oncology Announces Multiple Data Presentations At Society Of Gynecologic Oncology 2025 Annual Meeting On Women's CancerRE Jan. 31B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy RatingMT ...
IVT or Linea DNA platforms approved for human therapeutic use, our need to raise substantial additional funds, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including its Annual Re...
(structured, semi-structured, and unstructured). Straive's solutions employ cognitive technologies to automate data processing and deliver actionable insights from information-heavy content in any format, such as PDFs, emails, word files, annual reports, sustainability reports, scanned PDFs, images, ...